Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:1781 |
Name | thyroid cancer |
Definition | An endocrine gland cancer located in the thyroid gland located in the neck below the thyroid cartilage. |
Source | DiseaseOntology.org |
Alt Ids | DOID:10008 |
Path | disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer thyroid cancer |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01182285 | Phase II | Liothyronine sodium Valproic acid | A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin | Completed | USA | 0 |
NCT01236547 | Phase II | Paclitaxel Pazopanib | Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer | Completed | USA | 0 |
NCT01240590 | Phase Ib/II | Cisplatin + Crolibulin Cisplatin | A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) | Completed | USA | 0 |
NCT01263951 | Phase II | Everolimus + Sorafenib | Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone | Unknown status | USA | 0 |
NCT01270321 | Phase II | Pasireotide Everolimus | A Trial of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer | Completed | USA | 0 |
NCT01438554 | Phase I | Pazopanib + Trametinib | Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma | Completed | USA | 0 |
NCT01543763 | Phase I | Panobinostat + Pazopanib | Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors | Active, not recruiting | USA | 0 |
NCT01811212 | Phase II | Cabozantinib | Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer | Completed | USA | 0 |
NCT01843062 | Phase III | Selumetinib | Study Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer | Terminated | USA | SWE | POL | ITA | FRA | DNK | DEU | BRA | 0 |
NCT01876784 | Phase III | Vandetanib | Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer | Completed | USA | SWE | POL | ITA | FRA | ESP | DNK | CZE | BRA | 3 |
NCT01947023 | Phase I | Dabrafenib + Lapatinib | Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT02012231 | Phase Ib/II | PLX8394 | Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. | Terminated | USA | 0 |
NCT02034110 | Phase II | Dabrafenib + Trametinib | Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers | Completed | USA | SWE | NOR | NLD | ITA | FRA | ESP | DNK | DEU | CAN | BEL | AUT | 2 |
NCT02041260 | Phase II | Cabozantinib | A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting | Unknown status | USA | 0 |
NCT02143726 | Phase II | Sorafenib Everolimus | Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Thyroid Cancer | Unknown status | USA | 0 |
NCT02244463 | Phase II | Sapanisertib | A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer | Completed | USA | 0 |
NCT02289144 | Phase II | Ceritinib | Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer | Withdrawn | USA | 0 |
NCT02383927 | Phase II | Tipifarnib | Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations | Completed | USA | NLD | ITA | GRC | GBR | FRA | ESP | DEU | BEL | 1 |
NCT02432274 | Phase Ib/II | Etoposide Lenvatinib Cyclophosphamide | Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies | Completed | USA | ITA | GBR | FRA | ESP | DEU | 0 |
NCT02576431 | Phase II | Larotrectinib | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) | Active, not recruiting | USA | TUR | SWE | SVK | ITA | IRL | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 9 |
NCT02657369 | Phase II | Lenvatinib | A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC) | Terminated | USA | ITA | GBR | FRA | AUS | 0 |
NCT02688608 | Phase II | Pembrolizumab | Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer | Completed | USA | 0 |
NCT02721732 | Phase II | Pembrolizumab | Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors | Active, not recruiting | USA | 0 |
NCT02973997 | Phase II | Lenvatinib + Pembrolizumab | Pembrolizumab and Lenvatinib in Treating Metastatic or Recurrent Differentiated Thyroid Cancer That Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT03002623 | Phase II | CUDC-907 | CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer | Terminated | USA | 0 |
NCT03085056 | Phase I | Paclitaxel + Trametinib | Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer | Active, not recruiting | USA | 0 |
NCT03099356 | Phase II | Cyclophosphamide + Sirolimus | Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer | Recruiting | USA | 0 |
NCT03122496 | Phase I | Durvalumab + Tremelimumab | Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer | Completed | USA | 0 |
NCT03131206 | Phase Ib/II | Alectinib | A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer | Terminated | USA | 0 |
NCT03139747 | Phase II | Everolimus + Lenvatinib | UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone | Suspended | USA | 0 |
NCT03157128 | Phase Ib/II | Selpercatinib | A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (LIBRETTO-001) | Active, not recruiting | USA | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CHE | CAN | AUS | 5 |
NCT03211117 | Phase II | Docetaxel + Doxorubicin + Pembrolizumab | Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer | Completed | USA | 0 |
NCT03246958 | Phase II | Ipilimumab + Nivolumab | Nivolumab Plus Ipilimumab in Thyroid Cancer | Active, not recruiting | USA | 0 |
NCT03360890 | Phase II | Docetaxel + Pembrolizumab | Synergy of Pembrolizumab Anti-PD-1 Immunotherapy With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors | Suspended | USA | 0 |
NCT03506048 | Phase II | Lenvatinib | Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer | Terminated | USA | 0 |
NCT03630120 | Phase II | Lenvatinib + Sorafenib Cabozantinib + Vandetanib | Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer | Terminated | USA | 0 |
NCT03690388 | Phase III | Cabozantinib | A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy | Active, not recruiting | USA | ROU | POL | NLD | ITA | ISR | HUN | HRV | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 6 |
NCT03753919 | Phase II | Durvalumab + Tremelimumab | Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial (DUTHY) | Terminated | ESP | 0 |
NCT03936959 | Phase I | LY3434172 | A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer | Completed | USA | FRA | BEL | AUS | 1 |
NCT03975231 | Phase I | Dabrafenib + Trametinib | Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer | Recruiting | USA | 0 |
NCT04061980 | Phase II | Binimetinib + Encorafenib Binimetinib + Encorafenib + Nivolumab | Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer | Active, not recruiting | USA | 0 |
NCT04321954 | Phase II | Lenvatinib | Lenvatinib in Locally Advanced Invasive Thyroid Cancer | Recruiting | USA | 0 |
NCT04420754 | Phase I | AIC100 | Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer | Recruiting | USA | 0 |
NCT04552769 | Phase II | Abemaciclib | Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer | Active, not recruiting | USA | 0 |
NCT04682431 | Phase I | Pembrolizumab + PY159 PY159 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
NCT04706962 | Phase I | TH1902 | TH1902 in Patients With Advanced Solid Tumors | Recruiting | USA | CAN | 0 |
NCT04940052 | Phase III | Dabrafenib + Trametinib | Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer | Active, not recruiting | USA | TUR | CAN | BRA | ARG | 6 |
NCT05182931 | Phase II | Dabrafenib + Trametinib Trametinib | A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study) (I-FIRST) | Recruiting | AUS | 0 |
NCT05275374 | Phase Ib/II | BI 882370 + Trametinib BI 882370 | XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (ENHANCE) | Not yet recruiting | 0 | |
NCT05652855 | Phase Ib/II | MHB088C | Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |
NCT05668962 | Phase II | Selpercatinib | Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC | Recruiting | USA | 0 |
NCT05718557 | Phase I | PYX-106 | Study of PYX-106 in Solid Tumors | Recruiting | USA | ESP | BEL | 0 |
NCT05720117 | Phase I | PYX-201 | Study of PYX-201 in Solid Tumors | Recruiting | USA | ESP | BEL | 0 |
NCT05785728 | Phase Ib/II | DB-1202 | A Phase 1/2 Study of DB-1202 Monotherapy in Advanced Solid Tumors | Not yet recruiting | 1 | |
NCT06638931 | Phase II | Nivolumab | Agnostic Therapy in Rare Solid Tumors (ANTARES) | Recruiting | BRA | 0 |
NCT06639191 | Phase I | 177Lu-AKIR001 | [177Lu]Lu-AKIR001 First-in-human Study (AKIR001) | Not yet recruiting | SWE | 0 |